Rua Bioscience Limited (NZE:RUA)
New Zealand · Delayed Price · Currency is NZD 0.0420
+0.0010 (2.44%)
Oct 3, 2025, 4:29 PM NZST
Rua Bioscience Revenue
In the fiscal year ending June 30, 2025, Rua Bioscience had annual revenue of 1.83M NZD with 477.39% growth. Rua Bioscience had revenue of 937.36K in the half year ending June 30, 2025, with 119.43% growth.
Revenue
1.83M
Revenue Growth
+477.39%
P/S Ratio
5.48
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | 1.51M | 477.39% |
| Jun 30, 2024 | 316.35K | -352.13K | -52.68% |
| Jun 30, 2023 | 668.48K | 23.39K | 3.63% |
| Jun 30, 2022 | 645.10K | 285.76K | 79.52% |
| Jun 30, 2021 | 359.34K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fisher & Paykel Healthcare Corporation | 2.02B |
| EBOS Group | 13.24B |
| Summerset Group Holdings | 340.08M |
| Ryman Healthcare | 759.16M |
| Oceania Healthcare | 260.57M |
| AFT Pharmaceuticals | 208.02M |
| Pacific Edge | 22.75M |
| Green Cross Health | 523.76M |